Company intelligence / Profile preview

Cessatech

Ownership: Private
Employees: ~6
Development stage: Phase 3

Overview

Cessatech’s lead product, CT001, is an analgesic nasal spray designed to treat acute pain in children. It leverages more than ten years of clinical experience with the active compound. The company uses a de-risked approach by repositioning existing medicines to fit pediatric needs, resulting in shorter development timelines and higher likelihood of regulatory success. Recent milestones include completion of pivotal studies and positive regulatory opinions under EU MDR

Therapeutic areas: OtherNeurology
Modalities: Nasal sprays (drug-device combination)Local anesthetic gel
Industry: Biotech

Drug pipeline

3 assets

CT001 (Cessatech)

2 more assets in the full pipeline.

Partnerships

Proveca Ltd.: Exclusive commercial partnership worldwide excluding the US for CT001Ventis Pharma Corporation – collaboration/license agreement on formulation/pain management therapies

Beyond the preview

Go deeper on Cessatech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cessatech.